争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 1 条
2022
Alnylam 就脂质专利起诉 Moderna 和 Pfizer
提起诉讼
Alnylam 在特拉华州联邦法院起诉 Moderna 和 Pfizer，指控两家公司的新冠疫苗侵犯其可生物降解脂质专利。Alnylam 称其寻求金钱赔偿，并表示无意阻碍疫苗销售、生产或分销。Moderna 否认相关指控；报道刊出时 Pfizer 尚未回应媒体。
品牌回应
否认 — Moderna
“Moderna’s LNPs do not resemble Alnylam’s work, and any assertion that the Alnylam patent covers Moderna’s Covid-19 vaccine is specious,” the company said.
来源摘录
Alnylam alleges that the company’s FDA-approved Covid vaccine, Spikevax, uses biodegradable LNP technology that infringes on the biodegradable lipids patent.
The two lawsuits were filed Thursday in federal court in Delaware.
Alnylam did not have similar meetings with Pfizer or BioNTech, but the company claims that their FDA-approved Covid vaccine, Comirnaty, uses LNPs that infringe the same patent.